Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aura Biosciences, Inc. (AURA : NSDQ)
 
 • Company Description   
Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 52

 
 • Price / Volume Information   
Yesterday's Closing Price: $16.32 Daily Weekly Monthly
20 Day Moving Average: 48,040 shares
Shares Outstanding: 29.26 (millions)
Market Capitalization: $477.52 (millions)
Beta:
52 Week High: $26.16
52 Week Low: $13.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.80% 2.13%
12 Week -8.83% -1.07%
Year To Date -3.89% 14.29%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
85 BOLTON STREET
-
CAMBRIDGE,MA 02140
USA
ph: 617-500-8864
fax: -
aura@argotpartners.com http://www.aurabiosciences.com
 
 • General Corporate Information   
Officers
Elisabet de los Pinos - President and Chief Executive Officer
David Johnson - Chairman of the Board of Directors
Julie Feder - Chief Financial Officer
Giovanni Mariggi - Director
Anthony Mattessich - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 05153U107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 29.26
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $477.52 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.03 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.38
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - 27.90
12/31/21 - 21.14
09/30/21 - 14.31
Quick Ratio
03/31/22 - 27.90
12/31/21 - 21.14
09/30/21 - 14.31
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.82
12/31/21 - 5.21
09/30/21 - -4.61
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - -
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - -
 

Powered by Zacks Investment Research ©